Korro Bio, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Korro Bio, Inc. (KRRO) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $16.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Income Statement
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2023-11-02
- Korro Bio, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2023-09-30 was $16.00K, a 0.00% change year-over-year.
- Korro Bio, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2023-06-30 was $58.00K.
- Korro Bio, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2023-03-31 was $134.00K.
- Korro Bio, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2022-12-31 was $178.00K.
- Korro Bio, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$136.00K.
- Korro Bio, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2021 was -$89.00K.
- Korro Bio, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2020 was -$27.00K, a 150.00% decline from fiscal 2019.
- Korro Bio, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2019 was $54.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2023-09-30 | $16.00K 10-Q · filed 2023-11-02 | $74.00K derived: sum of 2 quarters · filed 2023-11-02 | $208.00K 10-Q · filed 2023-11-02 | $386.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | $58.00K 10-Q · filed 2023-08-10 | $192.00K 10-Q · filed 2023-08-10 | $370.00K derived: sum of 3 quarters · filed 2023-08-10 | $386.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-03-31 | $134.00K 10-Q · filed 2023-05-12 | $312.00K derived: sum of 2 quarters · filed 2023-05-12 | $328.00K derived: sum of 3 quarters · filed 2023-11-02 | $232.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-12-31 | $178.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $194.00K derived: sum of 2 quarters · filed 2023-11-02 | $98.00K derived: sum of 3 quarters · filed 2023-11-02 | -$136.00K 10-K · filed 2023-03-10 |
| 2022-09-30 | $16.00K 10-Q · filed 2023-11-02 | -$80.00K derived: sum of 2 quarters · filed 2023-11-02 | -$314.00K 10-Q · filed 2023-11-02 | -$379.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$96.00K 10-Q · filed 2023-08-10 | -$330.00K 10-Q · filed 2023-08-10 | -$395.00K derived: sum of 3 quarters · filed 2023-08-10 | -$399.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$234.00K 10-Q · filed 2023-05-12 | -$299.00K derived: sum of 2 quarters · filed 2023-05-12 | -$303.00K derived: sum of 3 quarters · filed 2023-05-12 | -$306.00K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | -$69.00K derived: sum of 2 quarters · filed 2023-03-10 | -$72.00K derived: sum of 3 quarters · filed 2023-03-10 | -$89.00K 10-K · filed 2023-03-10 |
| 2021-09-30 | -$4.00K 10-Q · filed 2022-11-08 | -$7.00K derived: sum of 2 quarters · filed 2022-11-08 | -$24.00K 10-Q · filed 2022-11-08 | -$41.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$3.00K 10-Q · filed 2022-08-09 | -$20.00K 10-Q · filed 2022-08-09 | -$37.00K derived: sum of 3 quarters · filed 2022-08-09 | -$53.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$17.00K 10-Q · filed 2022-05-04 | -$34.00K derived: sum of 2 quarters · filed 2022-05-04 | -$50.00K derived: sum of 3 quarters · filed 2022-05-04 | $25.00K derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | -$17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$33.00K derived: sum of 2 quarters · filed 2022-03-15 | $42.00K derived: sum of 3 quarters · filed 2022-03-15 | -$27.00K 10-K · filed 2022-03-15 |
| 2020-09-30 | -$16.00K 10-Q · filed 2021-11-15 | $59.00K derived: sum of 2 quarters · filed 2021-11-15 | -$10.00K 10-Q · filed 2021-11-15 | -$72.00K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $75.00K 10-Q · filed 2021-08-12 | $6.00K 10-Q · filed 2021-08-12 | -$56.00K derived: sum of 3 quarters · filed 2021-08-12 | -$90.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$69.00K 10-Q · filed 2021-05-13 | -$131.00K derived: sum of 2 quarters · filed 2021-05-13 | -$165.00K derived: sum of 3 quarters · filed 2021-05-13 | -$85.00K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | -$62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | -$96.00K derived: sum of 2 quarters · filed 2021-03-29 | -$16.00K derived: sum of 3 quarters · filed 2021-03-29 | $54.00K 10-K · filed 2021-03-29 |
| 2019-09-30 | -$34.00K 10-Q · filed 2020-11-16 | $46.00K derived: sum of 2 quarters · filed 2020-11-16 | $116.00K 10-Q · filed 2020-11-16 | |
| 2019-06-30 | $80.00K 10-Q · filed 2020-08-12 | $150.00K 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $70.00K 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |